July 2 2020 | Targeted Therapies in Oncology

August 03, 2020

In the face of canceled medical meetings this spring, continuing medical education offerings from Physicians’ Education Resource, LLC® were quickly transitioned from an in-person format to virtual presentations that have the ability to reach more medical specialists nationwide.

July 27, 2020

Like never before, presentations related to systemic therapies for biliary tract cancers are taking center stage at medical and oncology conferences, generating hope that treating physicians will have multiple options in the near future.

July 25, 2020

A survey by MJH Life Science reveals how patient communication has evolved across clinical practices in the wake of COVID-19.

July 25, 2020

The efficacy of each combination therapy targeting KRAS will likely depend on the tumor lineage, said Gordon Mills, MD, PhD.

July 24, 2020

“In both subgroups, the benefit of veliparib was durable, with an increased probability of remaining progression free at 2 and 3 years compared with placebo,”

July 21, 2020

A pathogenic germline mutation rate of about 5% has been identified in women who had a family history of breast or ovarian cancer but no personal history of either disease.

July 19, 2020

Even as the United States slowly opens back up with restrictions on nonessential businesses easing, coronavirus disease 2019 has left an indelible mark on human history.

July 18, 2020

Exciting new knowledge and a more exquisite understanding of the role of tumor cell biology and the tumor microenvironment have driven the fields of precision oncology/genomics-based medicine and immuno-oncology/cancer immunotherapy.

July 15, 2020

Agents developed to prevent myelosuppression are the latest chemoprotectants under investigation in the treatment of various solid tumor malignancies.